Insert Therapeutics Presents Capabilities and Versatility of Drug Delivery Platform
September 10, 2003 14:17 ET
|
Insert Therapeutics, Inc.
PASADENA, Calif., Sept. 10, 2003 (PRIMEZONE) -- Insert Therapeutics, Inc. Senior Scientist Jianjun Cheng, PhD, presented data this week at the American Chemical Society Meeting in New York City...
Insert Therapeutics Receives Phase I FLAIR Grant to Further its Novel, Non-Viral Gene Delivery System for Treating Cancer; National Cancer Institute Awards Phase I Grant for Cyclosert Delivery of Interferon Alpha Gene
July 24, 2003 08:00 ET
|
Insert Therapeutics, Inc.
PASADENA, Calif., July 24, 2003 (PRIMEZONE) -- Insert Therapeutics, Inc. announced that it has been awarded a Phase I Flexible System to Advance Innovative Research (FLAIR) grant from the National...
Insert Therapeutics Describes In Vivo Performance and Versatility of Drug Delivery Platform
July 22, 2003 08:00 ET
|
Insert Therapeutics, Inc.
PASADENA, Calif., Jul 22, 2003 (PRIMEZONE) -- Insert Therapeutics, Inc. President and Chief Executive Officer, Leonard R. Borrmann, Pharm.D., presented data today demonstrating the flexibility and...
Insert Therapeutics Reports In Vivo Performance of Drug Delivery Platform Assembled with a Nucleic Acid
June 24, 2003 10:00 ET
|
Insert Therapeutics, Inc.
PASADENA, Calif., June 24, 2003 (PRIMEZONE) -- Insert Therapeutics, Inc. reported that its Senior Scientist Dr. Suzie Hwang Pun presented data on the company's proprietary Cyclosert(tm) drug delivery...